淋巴结阳性早期宫颈癌根治术后放化疗的风险分层:单中心回顾性研究
本研究回顾性纳入160例淋巴结阳性早期宫颈癌患者,均接受根治性子宫切除及淋巴结清扫后行调强放疗联合同期铂类化疗。中位随访39.7个月,3年无病生存率和总生存率分别为81.3%和93.7%。多因素分析显示非鳞癌组织学类型和淋巴结转移≥4个是DFS的独立不良预后因素,据此构建的风险分层系统将患者分为低危和高中间危组,两组DFS和OS差异显著。
要点
- 非鳞癌组织学类型和淋巴结转移≥4个是淋巴结阳性早期宫颈癌根治术后放化疗患者DFS的独立不良预后因素。
- 基于上述因素构建的风险分层系统将患者分为低危组(无危险因素,n=108)和高中间危组(1或2个危险因素,n=52),两组3年DFS和OS差异显著。
- 对于非鳞癌或淋巴结转移≥4个的患者,巩固化疗未带来额外生存获益,提示需要创新治疗策略。
核心结论
- 淋巴结阳性早期宫颈癌根治术后放化疗的结局存在异质性,非鳞癌组织学类型和淋巴结转移≥4个是DFS的独立不良预后因素。
- 基于非鳞癌组织学类型和淋巴结转移≥4个构建的风险分层系统可区分低危和高中间危组,高中间危组DFS和OS显著更差。
- 对于非鳞癌或淋巴结转移≥4个的患者,巩固化疗未 confer 额外生存获益,提示需要创新治疗策略。
研究设计与样本
- 单中心回顾性研究,纳入2013年1月至2024年10月在本机构接受根治性子宫切除和淋巴结清扫后行同期放化疗的连续淋巴结阳性宫颈癌患者。
- 排除有宫旁浸润或切缘阳性的患者,所有患者接受现代容积旋转调强放疗联合同期铂类化疗。
- 共纳入160例患者,中位年龄44岁,中位淋巴结检出数33个,11例有腹主动脉旁淋巴结转移。
- 采用单因素和多因素Cox回归分析识别与DFS和OS相关的因素,并据此进行风险分层。
主要发现
- 中位随访39.7个月,31例患者出现疾病进展,12例死亡,3年DFS和OS分别为81.3%和93.7%。
- 多因素分析显示非鳞癌组织学类型(HR 1.526,95%CI 1.044-2.232,p=0.029)和淋巴结转移≥4个(HR 1.521,95%CI 1.027-2.252,p=0.036)是DFS的独立不良预后因素。
- 风险分层系统将患者分为低危组(无危险因素,n=108)和高中间危组(1或2个危险因素,n=52)。
- 高中间危组较低危组DFS和OS显著更差:3年DFS 67.4% vs 87.3%(HR 1.697,95%CI 1.192-2.417,p=0.002);3年OS 82.5% vs 98.8%(HR 3.577,95%CI 1.668-7.667,p<0.001)。
关键数值与推荐
- 非鳞癌组织学类型:DFS的HR 1.526(95%CI 1.044-2.232,p=0.029)。
- 淋巴结转移≥4个:DFS的HR 1.521(95%CI 1.027-2.252,p=0.036)。
- 高中间危组 vs 低危组:3年DFS 67.4% vs 87.3%(HR 1.697,95%CI 1.192-2.417,p=0.002);3年OS 82.5% vs 98.8%(HR 3.577,95%CI 1.668-7.667,p<0.001)。
临床怎么用
- 对于淋巴结阳性早期宫颈癌根治术后患者,可根据非鳞癌组织学类型和淋巴结转移≥4个进行风险分层,高中间危组需更密切随访。
- 非鳞癌或淋巴结转移≥4个的患者接受巩固化疗未显示额外生存获益,应审慎选择巩固化疗。
局限性
- 单中心回顾性研究,样本量有限(160例),结果需外部验证。
- 排除了宫旁浸润或切缘阳性的患者,结论适用范围受限。
- 中位随访39.7个月,长期生存结局尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited data exist on the effectiveness of concurrent chemoradiotherapy (CRT) using intensity-modulated radiation therapy (IMRT) after radical surgery in patients with node-positive early-stage cervical cancer. This study aimed to identify prognostic factors and categorize patients into risk groups for personalized adjuvant therapy. METHODS: The study included consecutive patients with pathologically confirmed node-positive cervical cancer who underwent radical hysterectomy and lymphadenectomy followed by CRT from January 2013 to October 2024 at our institute. Patients with parametrial invasion or positive resection margins were excluded. All patients received modern volumetric-modulated arc therapy with platinum-based concurrent chemotherapy. Data on clinicopathologic features, treatment details, and oncologic outcomes were collected. Univariate and multivariate Cox regression analyses were conducted to identify factors associated with disease-free survival (DFS) and overall survival (OS). Patients were further stratified into distinct risk categories for recurrence based on identified prognostic factors. RESULTS: A total of 160 patients were included, with a median age of 44 years. The median number of lymph nodes retrieved was 33, and 11 patients presented with para-aortic lymph node metastasis (LNM). Over a median follow-up period of 39.7 months, 31 patients experienced disease progression, and 12 succumbed to the disease, yielding 3-year DFS and OS rates of 81.3% and 93.7%, respectively. Multivariate analysis identified non-squamous histotype (hazard ratio [HR]: 1.526, 95% confidence interval [CI]: 1.044-2.232, p = 0.029) and LNM ≥ 4 (HR: 1.521, 95% CI: 1.027-2.252, p = 0.036) as independent predictors of poorer DFS. Utilizing these prognostic factors for DFS, a risk stratification system was developed, categorizing patients into low-risk (no risk factors, n = 108) and high-intermediate risk (one or two risk factors, n = 52) groups. The high-intermediate-risk group exhibited significantly inferior DFS and OS compared to the low-risk group (3-year DFS: 67.4% versus 87.3%, HR: 1.697, 95% CI: 1.192-2.417, p = 0.002; 3-year OS: 82.5% versus 98.8%, HR: 3.577, 95% CI: 1.668-7.667, p < 0.001, respectively). CONCLUSIONS: Node-positive early-stage cervical cancer exhibits heterogeneous outcomes following radical hysterectomy and postoperative CRT. In patients with non-SCC histotype or ≥ 4 LNM, consolidation chemotherapy does not confer an additional survival benefit, indicating a need for innovative therapeutic strategies.
引用
- Jia SZ, Yang D, Yang XJ, et al. Risk stratification of node-positive early-stage cervical cancer treated with radical hysterectomy followed by chemoradiotherapy: a retrospective single-center study. Radiat Oncol. 2025. PMID: 40361146. doi:10.1186/s13014-025-02655-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。